Government News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 
  • India and Brazil Sign MoU to Boost Pharmaceutical Regulatory Cooperation
    26 February 2026

    India and Brazil Sign MoU to Boost Pharmaceutical Regulatory Cooperation

    India and Brazil formalised a partnership to deepen cooperation in the regulation of pharmaceutical and medical products by signing a Memorandum of Understanding (MoU) between India’s Central Drugs Standard Control Organisation (CDSCO) and the Brazilian Health Regulatory Agency (ANVISA).
  • 26 February 2026
    India Transitions to Td Vaccine Under National Immunization Programme
    In a major step to strengthen the country’s immunization framework, Union Health Minister JP Nadda inaugurated the indigenously manufactured Tetanus and Adult Diphtheria (Td) vaccine at the Central Research Institute (CRI), Kasauli
  • 12 February 2026
    CDSCO Approves AstraZeneca’s Imfinzi for Advanced Endometrial Cancer in India
    AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import and market Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL, sold under the brand name Imfinzi, for an additional indication in India.
  • 9 February 2026
    Path Opens for CGHS Pharmacists to Become Gazetted Officers
    In a major and long-awaited development, the Central Government has notified the Recruitment Rules for the posts of Depot Manager (DM) and Assistant Depot Manager (ADM) under the Central Government Health Scheme (CGHS).
  • 3 February 2026
    IPC Urges Medical Device Companies to Strengthen Adverse Event Reporting Under MvPI
    The Indian Pharmacopoeia Commission (IPC), under the Ministry of Health and Family Welfare, has urged all Medical Device Marketing Authorisation Holders (MAHs) to ensure strict compliance with adverse event reporting under the Materiovigilance Programme of India (MvPI), stressing that timely reporting is critical to patient safety and effective regulatory oversight.
  • 2 February 2026
    Budget Boost to Make India a Global Biopharma Hub
    In a major push for India’s pharmaceutical and biopharmaceutical sectors, the Union Budget 2026-27, presented by Finance Minister Smt. Nirmala Sitharaman in Parliament today, announced comprehensive initiatives aimed at strengthening domestic capacity, fostering innovation and positioning India as a global biomanufacturing leader.
  • 29 January 2026
    CGHS notifies Senior Pharmacist RRs, grants Group ‘B’ Status amid dissent
    Central Government Health Scheme, CGHS, Ministry of Health and Family Welfare, marking a major structural shift in the pharmacy cadre. For the first time, CGHS pharmacists are eligible for promotion to a Group B, Non-Gazetted post.
  • 28 January 2026
    CDSCO eases Test Licence Pathway, cuts approval timelines under NDCT Rules Amendment 2026

    In a move aimed at accelerating drug development while maintaining regulatory oversight, India’s drug regulator has notified sweeping changes to the New Drugs and Clinical Trials (NDCT) Rules, 2019, introducing a faster “prior intimation” route for select test licences and sharply reducing approval timelines.

    The amendments, notified on January 20, 2026, under G.S.R. 46(E), mark a significant shift in how manufacturers can produce new drugs and investigational products for clinical trials, bioavailability, bioequivalence studies, and analytical testing

  • 27 January 2026
    How the India - EU Trade Deal Will Benefit the Pharmaceutical Sector

    The proposed India-European Union (EU) trade deal is expected to bring significant benefits to India’s pharmaceutical industry. The EU is one of the largest and most regulated medicine markets in the world, and easier access to this region can open new growth opportunities for Indian drug manufacturers. The agreement focuses not only on trade but also on regulatory cooperation, which is crucial for pharmaceuticals.

  • 22 January 2026
    Government reduces Clinical Trial and BA/BE approval time to 45 days
    One of the major changes is the reduction in approval timelines. The time limit for granting permissions related to clinical trials, bioavailability, and bioequivalence studies has been cut from 90 working days to 45 working days.
Subscribe to Government News